The present disclosure relates to compositions and probiotic formulations of bacterial isolates, and methods for selecting bacterial isolates capable of reducing levels of Salmonella and/or Campylobacter in poultry. Methods for reduction of Salmonella and/or Campylobacter in poultry are also part of the invention.

The invention relates to methods for identifying/selecting cows for immunisation and to the use of markers for such methods. The methods involve interrogation of cells from a cow, and the use of markers in those cells to identify cows for immunisation. Cows are selected for immunisation by observing the change in expression of markers resulting from stimulating a cell obtained from a cow with C. difficile and/or a C. difficile specific antigen.

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.

The present invention relates to a new cocktail of bacteriophages with specific lytic activity against Salmonella enteritidis, Salmonella typhimurium and Salmonella paratyphi B., for reducing, eliminating and/or preventing them in farm animals and animals from the poultry sector, such as poultry, hens and breeding hens, in addition to eggs. It may be administered as an additive in the feed, in water or by spray. Moreover, the cocktail may be used as a disinfectant in work areas of farms and abattoirs, and in processed foods, without affecting the organoleptic properties of the product.

This invention relates to the delivery of heterologous peptides or proteins such as therapeutic peptides, therapeutic proteins or antigens to mucosal sites using vesicles derived from the outer membrane of commensal bacteria, recombinant bacteria capable of producing such vesicles, and methods for the production of such vesicles. The invention further relates to an inducible expression system for use in recombinant bacteria.

The present investigation relates to a conjugate comprising flagellin adjuvant covalently linked to Vi polysaccharide derived from S. typhi for vaccination against typhoid. Both flagellin adjuvant and Vi polysaccharide are from S. typhi which leads to the improved immunogenicity. The conjugate of the present invention may be used as single dose administration without the need of multiple immunizations. The present invention also discloses a nanoparticle composition comprising the conjugate of the present invention.

The present invention relates to the field of antimicrobial agents active against Salmonella bacteria. In particular, the present invention relates to polypeptides comprising a first and a second amino acid sequence, wherein the first amino acid sequence is an endolysin, and wherein the second amino acid sequence is an antimicrobial peptide, cationic peptide, hydrophobic peptide, amphipathic peptide or sushi peptide, and wherein the polypeptide comprises at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 and derivatives thereof. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field and in the field of food and feed.

本发明公开了牛源肠炎沙门菌trxB基因缺失株的构建方法，以及牛源肠炎沙门菌trxB基因缺失能够降低牛源肠炎沙门菌的毒力，且牛源肠炎沙门菌trxB基因缺失能够应用于肠炎沙门菌疫苗。本发明利用Red同源重组方法构建牛源肠炎沙门菌trxB基因缺失株，并对其生物学特性和毒力进行研究，明确了trxB基因缺失引起牛源肠炎沙门菌毒力下降，为设计牛源肠炎沙门菌疫苗靶点提供参考，进而防治肠炎沙门菌感染，同时能够进步探索肠炎沙门菌TrxB蛋白的生理学功能。

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.

Compositions capable of enhancing and/or eliciting an immune response in a subject and methods of using the compositions. The compositions are capable of enhancing an IgA immune response and/or an IgG immune response and comprise an agent capable of reducing the level of binding of ATP to a P2X7 receptor to a subject. The compositions are for oral administration.

The invention relates to bird feed comprising synthetic capsaicinoids for prohylactic use or treatment of salmonella infection.

Methods that include combining a probe with a composition including a microorganism, wherein the probe includes a targeting portion that interacts with a phylogenetic surface marker (PSM) on the microorganism to at least partially coat the microorganism with the probe.

Provided herein is a Formulation of OmpA including a) OmpA protein as active molecule obtained as a product of OmpA gene inserted in a plasmid comprising a novel set of forward and reverse primer set, and b) Alginate chitosan nanoparticles as vehicle.

Antibody molecule-drag conjugates (ADCs) that specifically bind to lipopolysaceharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

本发明公开了种适于获得大量高纯度沙门氏菌外膜蛋白的提取方法与应用。该方法包括以下步骤：(1)将沙门氏菌外膜蛋白的基因克隆到表达载体中，然后将得到的重组表达载体导入到宿主沙门菌中，得到重组菌株；(2)将重组菌株扩大培养，再离心收集菌体并冷冻保存，得到冷冻菌体；(3)向冷冻菌体中加入蛋白裂解液，并加入苯甲基磺酰氟溶液，恒温超声破碎，收集蛋白质沉淀；(4)向蛋白质沉淀中加入外膜蛋白提取液，混匀后置于4℃条件下孵育，然后离心，收集上清液；(5)将上清液分离纯化，得到沙门氏菌外膜蛋白。本发明方法步骤简单、操作方便，适用于高纯度高活性外膜蛋白的大量提取，可同时满足蛋白活性、结构和疫苗研发等后续实验要求。

Adjuvants comprising chitosan cross-linked with, an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used, in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.

The present disclosure relates to nanoparticle compositions for use as vaccines against Salmonella. Disclosed herein is a composition comprising: a Salmonella enteritidis outer membrane protein (OMP) or Salmonella enteritidis killed whole antigenic extracted (KAg) protein; and a polyanhydride or chitosan nanoparticle. In some embodiments, the nanoparticle further comprises flagellar protein. Disclosed herein is a vaccine comprising: a composition comprising a Salmonella enteritidis OMP protein or Salmonella enteritidis killed whole antigenic extracted (KAg) protein; a polyanhydride or chitosan nanoparticle; and a pharmaceutically acceptable carrier.

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

The present invention relates to methods and kits for the rapid detection of the Escherichia coli O25b-ST131 clone. The inventors have isolated a podoviridae bacteriophage (LM33_P1) infecting the E. coli strain LM33 isolated from ventilator associated pneumonia and which belongs to clone STI3I-025b. By testing different strains of E coli belonging to 129 others various distinct serotypes (including twelve O25a) the inventors found that bacteriophage LM33_P1 is able to infect exclusively O25b strains (none of non-O25b strains could be infected by LM33_P1). The inventors have determined that the specificity displayed by bacteriophage LM33_P1 to infect only 025b serotype strains is based on a very specific polypeptide (Gp17) used by LM33_P1 to attach the bacterial cell via LPS molecule. In particular, the present invention relates to a polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence set forth in SEQ ID NO:1.

种鸭沙门氏菌减毒疫苗的制备方法，包括以下步骤，a、从易感染沙门氏菌的养鸭场内选取感染沙门氏菌的病变鸭子，分离出原始菌株SC26；b、分别经紫外、亚硝基胍诱变原始菌株SC26，获得各自最佳诱变条件，最佳诱变条件下细菌死亡率为80～90%左右，然后以各自最佳诱变条件进行紫外—亚硝基胍复合诱变，得到减弱的诱变菌株SC2261；c、将减弱的诱变菌株SC261扩大培养，制备沙门氏菌减毒疫苗。发明提供的鸭沙门氏菌减毒疫苗的制备方法，取发病区当地菌株，免疫原性针对性强，临床效果好，相当于专场专项疫苗。

This invention relates to devices and methods for purifying, detecting and using biological cells. A variety of cell types including viable tumor, stem, immune and sperm cells can be purified from a complex biological sample using a column, including a pipette tip column. Methods of the invention can aid research, diagnosis and treatment of cancer. Purified viable cells can be detected on the column or eluted from the column and detected. Cells on a column can be used as a stationary phase for liquid chromatography. Cells may be removed, recovered and analyzed.

A method for rapidly detecting S. typhimurium in milk through a Raman spectrum based on heavy water marking. The method comprises the steps of adding to-be-detected milk possibly containing S. typhimurium into culture media containing heavy water for culturing, then collecting cultured S. typhimurium cells and conducting Raman spectrum scanning, and analyzing and processing an obtained original Raman spectrum, so that S. typhimurium in the to-be-detected milk is detected. According to the method of the invention, D2O marking is adopted, and the Raman spectrum is used for rapidly detecting S. typhimurium in milk, so that the method has the advantages of being short in detection time (4-8 h), high in sensitivity, low in cost, easy to operate, convenient and fast to implement and the like; the detection limit is 104-108 cfu/mL, interference from the matrix in a milk sample is small, and the method is an ideal method for rapidly detecting S. typhimurium, has extremely good actual application prospects, and is suitable for being widely applied in the fields of food safety, environment monitoring and the like.

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.

The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.

The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.